4D Molecular Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
4D Molecular Therapeutics (4DMT) granted 13 new non-executive employees options to buy 260,000 shares and 157,600 RSUs. The biotech company focuses on gene therapies for retinal and cystic fibrosis diseases, with lead candidates 4D-150 and 4D-710 in clinical development.
Analysts from Barclays, Wells Fargo, and Chardan Capital provided ratings and price targets for 4D Molecular Therapeutics (FDMT), Pfizer (PFE), and Incyte (INCY). FDMT has a Strong Buy consensus with a $31.25 avg. target. PFE has a Moderate Buy consensus with a $29.62 avg. target. INCY has a Moderate Buy consensus with a $132.58 avg. target.
Kirn David (See Remarks) sold 58,333 shares of 4D Molecular Therapeutics, Inc. (FDMT) at an average of $12.92 ($12.92–$13.61, $0.75M total) across 2 trades on 2026-10-05 under a Rule 10b5-1 trading plan.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning FDMT (4D Molecular Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent FDMT coverage spans financial news, insider activity and market movers.
In the last 30 days, FDMT insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($754K). The most active reporter was Kirn David, See Remarks, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The grant modestly increases share count and may cause slight dilution pressure.
Analyst upgrades suggest upside potential.
Insider sale by a senior officer suggests potential downside pressure on FDMT.
Analyst coverage upgrade may support short-term price appreciation.
Mixed reaction; stock edged lower despite trial progress.
AlphAI scores every news story that mentions FDMT with an AI model for sentiment and relevance, and aggregates insider trades from 4D Molecular Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
4D Molecular Therapeutics (4DMT) granted 13 new non-executive employees options to buy 260,000 shares and 157,600 RSUs. The biotech company focuses on gene therapies for retinal and cystic fibrosis diseases, with lead candidates 4D-150 and 4D-710 in clinical development.
1 min readAnalysts from Barclays, Wells Fargo, and Chardan Capital provided ratings and price targets for 4D Molecular Therapeutics (FDMT), Pfizer (PFE), and Incyte (INCY). FDMT has a Strong Buy consensus with a $31.25 avg. target. PFE has a Moderate Buy consensus with a $29.62 avg. target. INCY has a Moderate Buy consensus with a $132.58 avg. target.
2 min readKirn David (See Remarks) sold 58,333 shares of 4D Molecular Therapeutics, Inc. (FDMT) at an average of $12.92 ($12.92–$13.61, $0.75M total) across 2 trades on 2026-10-05 under a Rule 10b5-1 trading plan.
1 min readB.Riley reiterated a Buy rating and $37.00 price target on 4D Molecular Therapeutics (FDMT), citing trial design and potential for its gene therapy candidate 4D-150. The company's market cap is $791 million, with shares up 91% year-to-date. Analysts highlight strong cash position, upcoming trial readouts, and potential adoption in wet AMD and diabetic macular edema.
2 min readOcular Therapeutix (OCUL) shares dropped 22% as competitors Kodiak Sciences (KOD) and 4D Molecular Therapeutics (FDMT) reported positive updates on their wet AMD treatments. KOD's DAYBREAK study met goals, while FDMT's 4D-150 showed lasting benefits. OCUL's AXPAXLI is in development, with FDA filing planned for late 2026.
2 min read4D Molecular Therapeutics, Inc. (FDMT) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 28, 2026, 4D Molecular Therapeutics, Inc. (the “Company”) reported that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema (“DME”). The
2 min readKirn David (See Remarks) sold 58,333 shares of 4D Molecular Therapeutics, Inc. (FDMT) at $13.90 ($0.81M total) on 2026-09-14 under a Rule 10b5-1 trading plan.
1 min readCompass Point upgraded Coinbase (COIN) to Neutral with a $177 price target, up from $130. Other upgrades include 4D Molecular Therapeutics (FDMT), Affirm (AFRM), Chime Financial (CHYM), and Bullish (BLSH) by their respective analysts. COIN closed at $175.26 on Friday.
2 min readOcular Therapeutix (OCUL) and 4D Molecular (FDMT) shares rose after EyePoint Pharmaceuticals (EYPT) reported its DURAVYU trial missed its primary goal. Clear Street maintained a 'Buy' rating on OCUL, while B. Riley set a $37 target for FDMT. EYPT's stock fell 67% on the news, with OCUL and FDMT gaining 6% and 19% respectively.
2 min readKirn David (See Remarks) sold 69,076 shares of 4D Molecular Therapeutics, Inc. (FDMT) at an average of $15.75 ($15.36–$16.42, $1.09M total) across 2 trades on 2026-08-19 under a Rule 10b5-1 trading plan.
1 min read
